13F Holdings
中文EN

AAWH Ascend Wellness Holdings, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756390 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-10.9%
TTM net income YoY-39.1%
TTM EPS YoY-45.0%
Revenue 3-yr CAGR7.2%
Net income 3-yr CAGR—

Margins

Gross margin33.9%
Operating margin-3.4%
Net margin-23.6%
FCF margin2.4%
EBITDA margin8.2%

Returns

ROE-1,004.3%
ROA-13.1%
ROIC (approx.)-6.1%
Asset turnover0.55x

Leverage & solvency

Liabilities / assets105.1%
Debt / equity—
Current ratio1.92x
Interest coverage-0.33x

Cash quality & payout

Operating cash flow / net income-0.32x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$500.58M$561.60M$518.59M$405.93M$332.38M
Cost of revenue$330.90M$377.39M$363.47M$271.36M$196.41M
Gross profit$169.68M$184.21M$155.12M$134.56M$135.97M
SG&A expense$169.69M$179.48M$158.74M$137.09M$116.67M
Operating income-$17.01M$4.73M-$3.62M-$7.53M-$17.20M
Interest expense$51.29M$45.26M$36.98M$32.44M$63.99M
Pretax income-$66.81M-$39.82M-$14.76M-$39.21M-$80.94M
Income tax$51.38M$45.17M$33.45M$41.69M$41.72M
Net income-$118.19M-$84.99M-$48.21M-$80.90M-$122.66M
EBITDA$56.52M$70.89M$55.36M$29.58M$5.01M
EPS (basic)-0.58-0.40-0.24-0.44-0.82
EPS (diluted)-0.58-0.40-0.24-0.44-0.82
Weighted avg. shares (diluted)203.48M212.43M199.15M183.38M149.43M
Banking
Loans, net——$13.12M$3.42M—
Balance sheet
Cash & equivalents$85.68M$88.25M$72.51M$74.15M$155.48M
Receivables$27.02M$36.54M$28.30M$14.10M$7.61M
Inventory$84.71M$89.55M$95.29M$97.53M$65.59M
Current assets$208.95M$229.38M$228.86M$198.74M$258.01M
PP&E, net$382.40M$260.46M$268.08M$279.86M$239.66M
Goodwill$58.45M$49.60M$47.54M$44.37M$42.97M
Intangibles$196.07M$205.50M$221.45M$221.09M$59.27M
Total assets$907.93M$900.43M$919.55M$872.16M$723.44M
Current liabilities$109.01M$144.54M$92.69M$110.95M$117.39M
Short-term debt$10.37M$72.69M$11.15M$11.33M$27.94M
Long-term debt$291.10M$214.42M$297.56M$319.30M$230.85M
Total debt$301.47M$287.11M$308.71M$330.63M$258.79M
Total liabilities$954.55M$828.63M$776.68M$708.75M$546.96M
Shareholders' equity-$47.44M$70.98M$142.87M$163.41M$176.48M
Net debt$215.80M$198.86M$236.21M$256.48M$103.31M
Shares outstanding202.22M205.03M206.88M188.06M171.59M
Cash flow statement
Operating cash flow$38.05M$73.29M$75.33M-$38.36M-$41.74M
Capital expenditure$26.01M$22.53M$24.25M$81.64M$88.43M
Free cash flow$12.04M$50.76M$51.09M-$120.00M-$130.17M
Investing cash flow-$45.74M-$37.20M-$59.89M-$114.25M-$113.23M
Financing cash flow$5.11M-$20.35M-$17.08M$71.28M$252.35M
Depreciation & amortization$73.53M$66.16M$58.98M$37.11M$22.22M
Stock-based compensation$2.45M$18.61M$19.78M$18.98M$23.09M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.